Biogen (XSWX:BIIB) Cyclically Adjusted Revenue per Share: CHF64.36 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIIB Biogen Inc XSWX:BIIB
69 GF Score
Price CHF173.46
GF Value CHF164.93
! 7 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted Revenue per Share?

Biogen XSWX:BIIB 69 Cyclically Adjusted Revenue per Share is CHF64.36 as of Mar. 2026. GuruFocus rates XSWX:BIIB with a GF Score™ of 69/100 and a GF Value™ of CHF164.93. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biogen's adjusted revenue per share for the three months ended in Mar. 2026 was CHF13.145. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF64.36 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biogen's average Cyclically Adjusted Revenue Growth Rate was 3.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biogen was 53.80% per year. The lowest was 5.10% per year. And the median was 21.20% per year.

As of today (2026-07-25), Biogen's current stock price is CHF173.46. Biogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was CHF64.36. Biogen's Cyclically Adjusted PS Ratio of today is 2.70.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 11.12. The lowest was 1.45. And the median was 4.84.


Biogen  (XSWX:BIIB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=173.46/64.36
=2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 11.12. The lowest was 1.45. And the median was 4.84.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biogen Cyclically Adjusted Revenue per Share Related Terms


Biogen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted Revenue per Share Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 64.36

XSWX:BIIB vs OGN, AMRN, SCLX: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PS Ratio falls into.


XSWX:BIIB
69GF Score
Biogen Inc XSWX:BIIB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=13.145/330.2130*330.2130
=13.145

Current CPI (Mar. 2026) = 330.2130.

Biogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 12.789 241.018 17.522
201609 13.111 241.428 17.933
201612 13.492 241.432 18.453
201703 13.038 243.801 17.659
201706 14.044 244.955 18.932
201709 13.987 246.819 18.713
201712 15.389 246.524 20.613
201803 14.021 249.554 18.553
201806 16.030 251.989 21.006
201809 16.493 252.439 21.574
201812 17.471 251.233 22.963
201903 17.724 254.202 23.024
201906 18.767 256.143 24.194
201909 19.361 256.759 24.900
201912 20.255 256.974 26.028
202003 19.587 258.115 25.058
202006 21.767 257.797 27.881
202009 19.649 260.280 24.928
202012 16.445 260.474 20.848
202103 16.447 264.877 20.504
202106 16.783 271.696 20.398
202109 17.257 274.310 20.774
202112 17.070 278.802 20.218
202203 15.942 287.504 18.310
202206 17.182 296.311 19.148
202209 16.861 296.808 18.759
202212 16.300 296.797 18.135
202303 15.699 301.836 17.175
202306 15.199 305.109 16.450
202309 15.720 307.789 16.865
202312 14.144 306.746 15.226
202403 13.950 312.332 14.749
202406 15.100 314.175 15.871
202409 14.299 315.301 14.975
202412 15.001 315.605 15.695
202503 14.652 319.799 15.129
202506 14.665 322.561 15.013
202509 13.718 324.800 13.947
202512 12.273 324.054 12.506
202603 13.145 330.213 13.145

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of CHF64.36 mean?
Biogen (XSWX:BIIB) has a Cyclically Adjusted Revenue per Share of CHF64.36 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biogen and its competitors.
Is Biogen's Cyclically Adjusted Revenue per Share too high?
Biogen's current Cyclically Adjusted Revenue per Share is CHF64.36. Overall, Biogen has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's Cyclically Adjusted Revenue per Share compare to OGN and AMRN?
Biogen's Cyclically Adjusted Revenue per Share of CHF64.36 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biogen and its competitors. Biogen's current Cyclically Adjusted Revenue per Share is CHF64.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current Cyclically Adjusted Revenue per Share of CHF64.36. The stock's GF Value™ is CHF164.93, compared to a current price of CHF173.46 — trading 5.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is CHF64.36. Biogen's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current Cyclically Adjusted Revenue per Share is CHF64.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (XSWX:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of CHF173.46 is trading 5.2% above its estimated GF Value™ of CHF164.93.

Key valuation signals for XSWX:BIIB:

  • Cyclically Adjusted Revenue per Share: CHF64.36
  • GF Value™: CHF164.93 vs. price of CHF173.46 (5.2% above fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
69GF Score

Get the complete analysis for XSWX:BIIB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF173.46
Price
CHF164.93
GF Value